Tissue Engineering

Kaitlin Fogg Uses Bioengineering to Advance Women's Health
Biotech & Bioprocessing Kaitlin Fogg Uses Bioengineering to Advance Women's Health

For decades, the medical community frequently overlooked the physiological complexities of the female reproductive system, often discarding crucial biological tissues as mere medical waste. This systemic neglect created a profound void in scientific understanding, leaving women’s health issues

UCLA Researchers Identify Genetic Weakness in Aggressive Cancers
Biotech & Bioprocessing UCLA Researchers Identify Genetic Weakness in Aggressive Cancers

The landscape of oncology has long been haunted by small cell neuroendocrine cancers, a group of highly aggressive malignancies that strike the lungs, prostate, and ovaries with devastating speed and a profound resistance to modern medicine. These tumors are notorious for their early metastasis and

Lab-Grown Esophagus Offers New Hope for Pediatric Patients
Research & Development Lab-Grown Esophagus Offers New Hope for Pediatric Patients

The field of pediatric surgery is currently witnessing a paradigm shift, moving away from purely mechanical repairs toward the biological reconstruction of complex organs. For children born with long-gap esophageal atresia, the challenge has always been the physical impossibility of connecting two

Retatrutide Shows Strong Results in Diabetes and Weight Loss
Biotech & Bioprocessing Retatrutide Shows Strong Results in Diabetes and Weight Loss

The landscape of metabolic medicine is undergoing a profound transformation as a single molecule demonstrates the unprecedented ability to simultaneously regulate blood sugar, suppress appetite, and accelerate caloric expenditure. Historically, treatments for metabolic disorders focused on a

EC Approves Imfinzi for Early-Stage Gastric Cancer Treatment
Biotech & Bioprocessing EC Approves Imfinzi for Early-Stage Gastric Cancer Treatment

The landscape of gastrointestinal oncology has shifted significantly as European regulators authorize a potent new weapon for combating aggressive tumors before they have the chance to spread. The European Commission has officially approved the use of AstraZeneca’s durvalumab, commercially known as

FDA Grants Orphan Drug Status to New Rare Blood Cancer Treatment
Biotech & Bioprocessing FDA Grants Orphan Drug Status to New Rare Blood Cancer Treatment

The landscape of hematologic oncology has long been a battlefield where patients and physicians fight a grueling war of attrition against diseases that are managed but rarely defeated. For those living with rare myeloproliferative neoplasms, the medical journey often feels like a series of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later